Core Viewpoint - The Hong Kong government has approved two supplemental new drug applications (sNDA) for the drug Selinexor (希维奥) by the company, allowing its use in treating multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma [1] Group 1: Drug Approvals - The approval includes the use of Selinexor in combination with Bortezomib and Dexamethasone (XVd) for adult patients with multiple myeloma who have received at least one prior therapy [1] - Selinexor is also approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL), specifically for those who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation due to follicular lymphoma [1]
德琪医药-B(06996)：希维奥®在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症